MBRX Moleculin Biotech Inc: Bathi saben siji saham sajrone 12 wulan pungkasan

Simbol resmi perusahaan Moleculin Biotech Inc (MBRX)

Moleculin Biotech, Inc. (MBRX) develops small molecules to combat aggressive cancer, leveraging high scientific credibility. R&D activities are accompanied by strict compliance with environmental regulations regarding chemical disposal. The current EPS YoY TTM trajectory, where the parameter equals 98.90, demonstrates the capitalization's resilience to Fed rates, which is critical for the success of anthracycline trials and patient survival rates.

Moleculin Biotech, Inc. (MBRX) - Bathi resik saben saham (EPS TTM) saka 11.02.2024 nganti 17.11.2026

Moleculin Biotech, Inc. - rincian analitis lan metrik utama (MBRX)

- data kapitalisasi saham perusahaan:
Analisis wiwitan perusahaan:MBRX, Moleculin
Produk sing diprodhuksi Moleculin

This indicator captures the dynamics of net income per share over a trailing twelve-month period, allowing for an assessment of the business's actual capitalization rate relative to previous periods. By analyzing the annual EPS TTM YoY trend, an investor can distinguish random market spikes from systemic growth, which is critically important for Moleculin Biotech, Inc. (MBRX) given its high capital burn rate and the toxicity risks associated with its oncology drug pipeline.